NEW YORK (GenomeWeb News) – Meridian Bioscience today reported essentially flat year-over-year sales growth for the second quarter, though adoption of its molecular diagnostic platform continued to accelerate.

For the three months ended March 31, revenues came in at $47.3 million, up a fraction of 1 percent from $47.2 million a year ago, and missing the average analyst estimate of $49.7 million.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Genome Research this week: multiplex genotyping of germline and somatic short tandem repeats, graph-based regularization, and more.

A lack of funding may lead more than two dozen research facilities in Australia to shut down in three months.

Researchers report that paternally inherited genes are more likely to be expressed in mice.

In PNAS this week: Akt3 amplification in glioma progression, Tibetan Plateau frog genome, and more.